Revolutionizing Blood Cancer Treatment: Emerging Therapies and Future Perspectives

Notice

This is an unedited manuscript accepted for publication and provided as an Article in Press for early access at the author’s request. The article will undergo copyediting, typesetting, and galley proof review before final publication. Please be aware that errors may be identified during production that could affect the content. All legal disclaimers of the journal apply.

Year : 2025 | Volume : 03 | Issue : 02 | Page :
    By

    Mritunjay Kumar Mahto,

  • Zulphakar Ali,

  • Kamalesh Mistry,

  • Aftab Alam,

  • Shesh Kumar,

  • Komal Maliwal,

  1. Research Scholar, Department of Pharmacy, Faculty of Pharmaceutical Science, Mewar University, Gangrar, Chittorgarh, Rajasthan, India
  2. Assistant Professor, Department of Pharmacy, Faculty of Pharmaceutical Science, Mewar University, Gangrar, Chittorgarh, Rajasthan, India
  3. Assistant Professor, Department of Pharmacy, Faculty of Pharmaceutical Science, Mewar University, Gangrar, Chittorgarh, Rajasthan, India
  4. Lecturer, Department of Pharmacy, Faculty of Pharmaceutical Science, Mewar University, Gangrar, Chittorgarh, Rajasthan, India
  5. Research Scholar, Department of Pharmacy, Faculty of Pharmaceutical Science, Mewar University, Gangrar, Chittorgarh, Rajasthan, India
  6. Lecturer, Department of Pharmacy, Faculty of Pharmaceutical Science, Mewar University, Gangrar, Chittorgarh, Rajasthan, India

Abstract

Blood cancer inclusive of leukemia, lymphoma and multiple myeloma poses a significant threat in the world today because of its multifactorial process and its non-amenable to standard therapies. Some of such approaches are immunotherapy, gene-editing technology and targeted small molecule inhibitors that have altered the nature of treatments. CAR T cell therapy is a molecular targeted therapy for cancers and several clinical studies have reported a huge success. Also, the immunotherapy has evolved with monoclonal antibodies and immune checkpoint inhibitors enhancing the rates of survival because of relapsed or refractory blood malignancies. Advanced technological tools like CRISPR-Cas9 offered a fresh way of eradicating gene disorders linked with hematologic malignancies. Of course, successes in hematopoietic stem cell transplantation associated with progress in regenerative medicine speak loudly and contributed to high improvement of treatment outcomes, especially among high risk patients. AI and machine learning have bypassed the drug development challenges in blood cancer treatment, strategized targeted therapies tailored for patients, and provide better diagnostic tests and biomarkers that will significantly enhance early diagnosis of the illnesses and there are issues that include therapy resistance, high costs of treatment, and issues of ethics of gene-editing technologies that still pose challenges. Forecast considering prospective future trends focuses on a versatile approach, introduction of combined therapy, and treatment methods that tailored to the patient’s condition. With the emergence of new generation therapies and utilizing artificial intelligence and precision medicine, the approaches to the treatment of blood cancer are on the verge of a revolutionary breakthrough true by plasma cell therapy, which gives hope for a long-term remission, and potentially cure.

Keywords: Blood cancer, leukemia, lymphoma, multiple myeloma, immunotherapy, gene editing, artificial intelligence, precision medicine

[This article belongs to International Journal of Biomedical Innovations and Engineering ]

How to cite this article:
Mritunjay Kumar Mahto, Zulphakar Ali, Kamalesh Mistry, Aftab Alam, Shesh Kumar, Komal Maliwal. Revolutionizing Blood Cancer Treatment: Emerging Therapies and Future Perspectives. International Journal of Biomedical Innovations and Engineering. 2025; 03(02):-.
How to cite this URL:
Mritunjay Kumar Mahto, Zulphakar Ali, Kamalesh Mistry, Aftab Alam, Shesh Kumar, Komal Maliwal. Revolutionizing Blood Cancer Treatment: Emerging Therapies and Future Perspectives. International Journal of Biomedical Innovations and Engineering. 2025; 03(02):-. Available from: https://journals.stmjournals.com/ijbie/article=2025/view=233251


References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):7-30.
  2. DeVita VT, Lawrence TS, Rosenberg SA, editors. DeVita, Hellman, and Rosenberg’s Cancer: Principles & Practice of Oncology. 12th ed. Philadelphia: Wolters Kluwer; 2025.
  3. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2024;42(11):3059-68.
  4. Jaffe ES, Arber DA, Campo E, Harris NL, Quintanilla-Fend L. Hematopathology. 2nd ed. Philadelphia: Elsevier; 2025.
  5. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: IARC Press; 2025.
  6. Pui CH, Evans WE. A 50-year journey to cure childhood acute lymphoblastic leukemia. Semin Hematol. 2024;61(3):185-95.
  7. Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2024;381(5):454-64.
  8. Gartrell RD, Marks DK, Hart TD, Li G, Davila ML. B-cell maturation antigen-specific chimeric antigen receptor T cells for multiple myeloma: clinical experience and future directions. Front Immunol. 2024;15:1234.
  9. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2024;380(18):1786-97.
  10. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2024;378(5):439-48.
  11. Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2024;382(14):1331-42.
  12. Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2024;384(8):705-16.
  13. Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2024;18(6):372-85.
  14. June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2024;359(6382):1361-5.
  15. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2024;5(177):177ra38.
  16. Fesnak AD, June CH, Levine BL. Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer. 2024;16(9):566-81.
  17. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2024;3(95):95ra73.
  18. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2024;371(16):1507-17.
  19. Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2024;7(303):303ra139.
  20. Kumar, S., Saha, S., Singh, K., Singh, T., Mishra, A. K., Dubey, B. N., & Singh, S. (2024). Beneficial effects of spirulina on brain health: A systematic review. Current Functional Foods, 3(1), Article e120124225622. https://doi.org/10.2174/0126668629269256231222092721
  21. RaviKKumar VR, Rathi S, Singh S, Patel B, Singh S, Chaturvedi K, Sharma B. A Comprehensive Review on Ulcer and Their Treatment. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2023 Dec 21;39:e20230006. doi: 10.62958/j.cjap.2023.006. PMID: 38755116.
  22. Singh, V., Arora, S., Akram, W., Alam, S., Kumari, L., Kumar, N., Kumar, B., Kumar, S., Agrawal, M., Singhal, M., Kumar, S., Singh, S., Singh, K., Saha, S., & Dwivedi, V. (2024). Involvement of molecular mechanism and biological activities of Pemirolast: A therapeutic review. New Emirates Medical Journal, 5, Article e02506882308410. https://doi.org/10.2174/0102506882308410240607053814
  23. Rajput DS, Gupta N, Singh S, Sharma B. A Comprehensive Review: Personalized Medicine for Rare Disease Cancer Treatment. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2023 Dec 23;39:e20230008. doi: 10.62958/j.cjap.2023.008. PMID: 38830754.
  24. Singh S, Chaurasia A, Rajput DS, Gupta N. Mucoadhesive Drug Delivery System and There Future Prospective: Are a Promising Approach for Effective Treatment? Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2023 Dec 20;39:e20230005. doi: 10.62958/j.cjap.2023.005. PMID: 38751344.
  25. Kumar, S., Saha, S., Sharma, B., Singh, S., Shukla, P., Mukherjee, S., Agrawal, M., Singh, K., & Singh, T. (2023). The role of resveratrol in Alzheimer’s disease: A comprehensive review of current research. Current Functional Foods, 2(2), Article e121223224364, 13 pages. https://doi.org/10.2174/0126668629269244231127071411
  26. Patel S, Ismail Y, Singh S, Rathi S, Shakya S, Patil SS, Bumrela S, Jain PC, Goswami P, Singh S. Recent Innovations and Future Perspectives in Transferosomes for Transdermal Drug Delivery in Therapeutic and Pharmacological Applications. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2024 Oct 24;40:e20240031. doi: 10.62958/j.cjap.2024.031. PMID: 39442957.
  27. Vaghela MC, Rathi S, Shirole RL, Verma J, Shaheen, Panigrahi S, Singh S. Leveraging AI and Machine Learning in Six-Sigma Documentation for Pharmaceutical Quality Assurance. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2024 Jul 18;40:e20240005. doi: 10.62958/j.cjap.2024.005. PMID: 39019923.
  28. Patel S, Ismail Y, Singh S, Rathi S, Shakya S, Patil SS, Bumrela S, Jain PC, Goswami P, Singh S. Recent Innovations and Future Perspectives in Transferosomes for Transdermal Drug Delivery in Therapeutic and Pharmacological Applications. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2024 Oct 24;40:e20240031. doi: 10.62958/j.cjap.2024.031. PMID: 39442957.
  29. Kumar, S., Saha, S., Pathak, D., Singh, T., Kumar, A., Singh, K., Mishra, A. K., Singh, S., & Singh, S. (2024). Cholesterol absorption inhibition by some nutraceuticals. Recent Advances in Food, Nutrition & Agriculture, 16(1), 2–11. https://doi.org/10.2174/012772574X285280240220065812
  30. Singh, S., Chaurasia, A., Rajput, D. S., & Gupta, N. (2024). An overview on mucoadhesive buccal drug delivery systems & approaches: A comprehensive review. African Journal of Biological Sciences (South Africa), 6(5), 522–541, DOI: 10.33472/AFJBS.6.5.2024.522-541
  31. Kumar, S., Singh, S., Rajput, D., Sharma, B., Chaturvedi, K., Singh, N., Saha, S., Singh, K., & Mukherjee, S. (2024). Pharmacological approaches and herbal interventions for Alzheimer’s disease. The Natural Products Journal, 14(8), Article e220124225945. https://doi.org/10.2174/0122103155275266231123090138
  32. Ravikkumar VR, Patel BD, Rathi S, Parthiban S, Upadhye MC, Shah AM, Rehan SSA, Samanta S, Singh S. Formulation and Evaluation of Drumstick Leaves Tablet as An Immunomodulator. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2024 Jun 21;40:e20240004. doi: 10.62958/j.cjap.2024.004. PMID: 38902996.
  33. Sharma, A., Bara, G., Keshamma, E., Sharma, B., Singh, S., Singh, S. P., Parashar, T., Rathore, H. S., Sarma, S. K., & Rawat, S. (2023). Cancer biology and therapeutics: A contemporary review. Journal of Cardiovascular Disease Research, 14(10), 1229-1247.
  34. Dewangan, H. K., Singh, S., Mishra, R., & Dubey, R. K. (2020). A review on application of nanoadjuvant as delivery system. International Journal of Applied Pharmaceutics, 12(4), 24–33. https://doi.org/10.22159/ijap.2020v12i4.36856
  35. Singh S, Chaurasia A, Gupta N, Rajput DS. Effect of Formulation Parameters on Enalapril Maleate Mucoadhesive Buccal Tablet Using Quality by Design (QbD) Approach. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2024 Jun 27;40:e20240003. doi: 10.62958/j.cjap.2024.003. PMID: 38925868.
  36. Patel SK, Prathyusha S, Kasturi M, Godse KC, Singh R, Rathi S, Bumrela S, Singh S, Goswami P. Optimizing Irbesartan Fast Dissolving Tablets Using Natural Polysaccharides for Enhanced Drug Delivery and Patient Compliance. Int Res J Multidiscip Scope (IRJMS). 2025;6(1):1181-1190. https://doi.org/10.47857/irjms.2025.v06i01.02542
  37. Park JH, Rivière I, Gonen M, Wang X, Sénéchal B, Curran KJ, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2024;378(5):449-59.
  38. Locke FL, Neelapu SS, Bartlett NL, Siddiqi T, Chavez JC, Hosing CM, et al. Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol Ther. 2024;25(1):285-95.
  39. Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak Ö, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2024;377(26):2545-54.
  40. Gauthier J, Hirayama AV, Purushe J, Hay KA, Lymp J, Li DH, et al. Factors associated with durable complete response after CD19 CAR T-cell therapy for refractory/relapsed B-cell lymphoma. J Clin Oncol. 2024;38(7):4142-54.
  41. Wang M, Fowler N, Wagner-Bartak N, Feng L, Karlin L, Keating M, et al. Safety and efficacy of venetoclax in combination with obinutuzumab in previously untreated patients with chronic lymphocytic leukemia. Blood. 2024;133(18):2047-55.
  42. Anderson KC, Carrasco RD. Pathogenesis of myeloma. Annu Rev Pathol. 2024;16:195-222.
  43. Dimopoulos MA, Terpos E, Boccadoro M, Delimpasi S, Musto P, Gramatzki M, et al. Elotuzumab plus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma. N Engl J Med. 2024;373(7):621-31.
  44. Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk stratification, and management. Am J Hematol. 2024;99(1):56-72.
  45. Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, et al. Carfilzomib, dexamethasone, and daratumumab for relapsed multiple myeloma. N Engl J Med. 2024;384(20):1818-31.
  46. Shah UA, Mailankody S. Emerging immunotherapies in multiple myeloma. BMJ. 2024;375:e066906.
  47. Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from the International Myeloma Working Group. J Clin Oncol. 2024;33(26):2863-9.
  48. Kumar SK, Callander NS, Hillengass J, Liedtke M, Baljevic M, Campagnaro E, et al. NCCN guidelines insights: multiple myeloma, version 3.2024. J Natl Compr Canc Netw. 2024;20(1):8-19.
  49. Hallek M, Shanafelt TD, Eichhorst B. Chronic lymphocytic leukaemia. Lancet. 2024;391(10129):1524-37.
  50. Byrd JC, Hillmen P, O’Brien S, Barrientos JC, Reddy NM, Coutre S, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the ASCEND trial. Blood. 2024;135(15):2041-9.
  51. Brown JR. How I treat CLL patients with ibrutinib. Blood. 2024;135(5):393-404.
  52. Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2024;379(26):2517-28.
  53. Davids MS, Hallek M. Pathogenesis and management of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2024;2024(1):12-23.
  54. Ghia P, Pluta A, Wach M, Carroll C, Andritsos L, Fox CP, et al. ASCEND: phase 3, randomized trial of acalabrutinib versus investigator’s choice in relapsed/refractory chronic lymphocytic leukemia. J Clin Oncol. 2024;38(25):2849-61.
  55. Kantarjian H, Ravandi F, Short NJ, Huang X, Jain N, Sasaki K, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2024;375(8):740-53.
  56. Short NJ, Kantarjian H, Pui CH. Novel therapies in acute lymphoblastic leukemia. Clin Cancer Res. 2024;28(10):2035-44.
  57. DiNardo CD, Lachowiez CA. Acute myeloid leukemia: from mutation profiling to treatment decisions. Hematology Am Soc Hematol Educ Program. 2024;2024(1):45-56.
  58. Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2024;373(12):1136-52.
  59. Pollyea DA, Stevens BM, Koenig K, Ahn Y, Winters A, Pei S, et al. Venetoclax with azacitidine disrupts leukemia stem cells in acute myeloid leukemia. Nat Med. 2024;24(2):185-91.
  60. O’Brien S, Pui CH. Precision medicine in leukemia: beyond BCR-ABL and JAK2. Blood. 2024;135(22):1955-62.
  61. Ferrando AA, López-Otín C. Clonal evolution in leukemia. Nat Med. 2024;26(3):369-78.
  62. DiPersio JF, Di Stasi A. Chimeric antigen receptor T-cell therapy in leukemia. Hematology Am Soc Hematol Educ Program. 2024;2024(1):208-18.
  63. Sallman DA, Asby S, Al Malki MM, Pollyea DA. Immunotherapies in acute myeloid leukemia. J Clin Oncol. 2024;42(5):445-60.
  64. Gribben JG, O’Brien S. Novel immunotherapies in hematologic malignancies. Blood. 2024;134(11):885-96.
  65. Zeiser R, Blazar BR. Pathophysiology of graft-versus-host disease and therapeutic targets. N Engl J Med. 2024;382(11):1027-39.
  66. Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2024;22(5):681-92.
  67. Al-Hamadani M, Habermann TM, Cerhan JR, Macon WR, Go RS. Non-Hodgkin lymphoma. Mayo Clin Proc. 2024;95(5):912-28.
Regular Issue Subscription Original Research
Volume 03
Issue 02
Received 15/04/2025
Accepted 08/09/2025
Published 29/11/2025
Publication Time 228 Days
105

Login


My IP

PlumX Metrics